Improving U.S. Drug Supply Stability Through Continuous Nanoparticle Processing
The U.S. pharmaceutical supply chain remains heavily reliant on international manufacturing. Approximately 80% of generic drugs and a significant share of active pharmaceutical ingredients (APIs) used in the U.S. are produced overseas, particularly in Asia. This dependency introduces a range of risk geopolitical conflicts, export restrictions, transportation delays, and natural disasters can disrupt access to essential medications and contribute to supply shortages or price volatility.
Efforts to increase U.S.-based manufacturing often encounter structural and operational barriers. Traditional pharmaceutical production methods, based on batch processing and manual operations, require significant capital, time, and space. These factors continue to slow domestic capacity expansion and limit responsiveness to supply chain disruptions.
Challenges in Domestic Biomanufacturing
Several persistent issues affect the development and scalability of pharmaceutical production in the U.S.:
- 1. Disjointed Processes
Drug manufacturing typically consists of separate steps—such as mixing, particle formation, purification, and packaging—each using distinct equipment and requiring manual transfers between units. These steps increase production time and introduce potential contamination risks. - 2. Scale-Up Barriers
Batch processes developed at small scales do not always translate efficiently to commercial production. Scale-up often requires new equipment, process revalidation, and added infrastructure, which increases cost and time. - 3. Product Variability
Manual interventions, open transfers, and storage between steps can introduce inconsistencies and elevate the likelihood of batch failures or quality deviations. - 4. Infrastructure Demands
Traditional facilities often require large cleanroom footprints, extensive staffing, and high utility consumption. These needs raise both capital expenditure (CapEx) and operating expenditure (OpEx), affecting overall production efficiency.
DIANT Pharma’s Continuous Nanoparticle Processing Technology
DIANT Pharma has developed an integrated continuous manufacturing platform designed for nanoparticle-based drug formulations, including lipid nanoparticles for mRNA, protein-drug conjugates, and targeted therapeutics. This platform consolidates critical production steps into a compact, automated, closed-loop system.
The system is designed to operate continuously and includes inline monitoring and automated control features. It combines nanoparticle formation, mixing, purification, and formulation within a single skid-mounted unit. The platform’s modular design supports throughput increases without requiring large-scale equipment or facility changes.
Features include:
- Integrated process flow eliminates manual transfers and reduces exposure to contaminants
- Inline sensors and automated controls for process monitoring and feedback
- Compact design that requires a smaller cleanroom footprint compared to traditional systems
- Automated cleaning and changeover systems that reduce downtime and labor requirements
Impact on U.S.-Based Manufacturing Operations
The implementation of DIANT’s platform into U.S. facilities may influence several aspects of pharmaceutical production:
- Deployment Speed
The platform’s compact footprint and integrated design can reduce the need for extensive facility retrofitting or new construction, affecting the time and resources required to initiate production. - Process Uniformity
Closed-loop processing with automated monitoring can limit product variability by reducing manual steps and off-line sampling, which may support more consistent outcomes. - Resource Efficiency
Lower facility and staffing requirements, combined with automated cleaning, can reduce overall resource use, contributing to lower operational costs in certain settings. - Localized Production
By facilitating the co-location of API and final drug product manufacturing, the platform can reduce exposure to international supply interruptions, import delays, or foreign regulatory constraints.
DIANT Pharma’s continuous nanoparticle manufacturing platform offers a transformative solution to the cost, speed, and complexity challenges in domestic drug production. By replacing traditional batch methods with a compact, continuous system, DIANT compresses the entire process into a smaller, more efficient footprint— dramatically reducing capital costs, infrastructure requirements, and deployment timelines.
The platform’s highly efficient mixing technology enables superior control and reproducibility of nanoparticle formulations, including mRNA-LNPs, while integrated automation in a closed-loop setup ensures consistent product quality and ease of scaleup.
As U.S. biopharmaceutical organizations adapt to shifting supply chain demands, DIANT’s technology presents a fast-to-deploy, cost-efficient manufacturing option designed for localized, resilient operations. This platform isn’t just a tool—it’s a strategy for enabling next-generation pharmaceutical production with speed, flexibility, and precision.